Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 77 Enz. Inhib. hit(s) with all data for entry = 7343
LigandPNGBDBM190471(US9181181, 9)
Affinity DataEC50:  930nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190472(US9181181, 10)
Affinity DataEC50:  2.10E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190473(US9181181, 11)
Affinity DataEC50:  810nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190474(US9181181, 12)
Affinity DataEC50:  58nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190475(US9181181, 13)
Affinity DataEC50:  30nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190476(US9181181, 14 | US9181181, 20)
Affinity DataEC50:  110nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190477(US9181181, 15 | US9181181, 19)
Affinity DataEC50:  840nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190479(US9181181, 17)
Affinity DataEC50:  1.80E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190477(US9181181, 15 | US9181181, 19)
Affinity DataEC50:  470nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190476(US9181181, 14 | US9181181, 20)
Affinity DataEC50:  72nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190459(US9181181, 22)
Affinity DataEC50:  1.80E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190460(US9181181, 23)
Affinity DataEC50:  53nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190461(US9181181, 24)
Affinity DataEC50:  5.20nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190462(US9181181, 25)
Affinity DataEC50:  43nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190483(US9181181, 26)
Affinity DataEC50:  73nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190484(US9181181, 27)
Affinity DataEC50:  1.40E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190463(US9181181, 28)
Affinity DataEC50:  2.50E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190464(US9181181, 29)
Affinity DataEC50:  760nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190465(US9181181, 30)
Affinity DataEC50:  1.70E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190466(US9181181, 31)
Affinity DataEC50:  3.50E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190467(US9181181, 32)
Affinity DataEC50:  3.00E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190485(US9181181, 33)
Affinity DataEC50:  1.80E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190486(US9181181, 34)
Affinity DataEC50:  1.50E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190487(US9181181, 35)
Affinity DataEC50:  6.00E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190488(US9181181, 36)
Affinity DataEC50:  7.00E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190489(US9181181, 37)
Affinity DataEC50:  3.90E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190490(US9181181, 38)
Affinity DataEC50:  9.00E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190491(US9181181, 39)
Affinity DataEC50:  1.80E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190492(US9181181, 40)
Affinity DataEC50:  8.20E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190493(US9181181, 41)
Affinity DataEC50:  3.80E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190494(US9181181, 42)
Affinity DataEC50:  4.20E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190495(US9181181, 43)
Affinity DataEC50:  4.20E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190496(US9181181, 44)
Affinity DataEC50:  1.10E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190453(US9181181, 1)
Affinity DataEC50:  240nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190454(US9181181, 2)
Affinity DataEC50:  240nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190455(US9181181, 3)
Affinity DataEC50:  56nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190456(US9181181, 4)
Affinity DataEC50:  1.40E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190457(US9181181, 5)
Affinity DataEC50:  200nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190468(US9181181, 6)
Affinity DataEC50:  330nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190469(US9181181, 7)
Affinity DataEC50:  1.80E+4nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190470(US9181181, 8)
Affinity DataEC50:  270nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190471(US9181181, 9)
Affinity DataEC50:  1.50E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190472(US9181181, 10)
Affinity DataEC50:  1.50E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190473(US9181181, 11)
Affinity DataEC50:  150nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


LigandPNGBDBM190475(US9181181, 13)
Affinity DataEC50:  12nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190476(US9181181, 14 | US9181181, 20)
Affinity DataEC50:  1.40E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190477(US9181181, 15 | US9181181, 19)
Affinity DataEC50:  130nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190478(US9181181, 16)
Affinity DataEC50:  1.10E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190479(US9181181, 17)
Affinity DataEC50:  4.40E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
In DepthDetails US Patent


LigandPNGBDBM190480(US9181181, 18)
Affinity DataEC50:  3.40E+3nMAssay Description:Transactivation Assay Expression vectors were prepared by inserting the ligand binding domain cDNA (complementary DNA) of human PPARalpha (amino acid...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


Displayed 1 to 50 (of 77 total ) | Next | Last >>
Jump to: